Latest Daunorubicin Stories
PRINCETON, N.J., April 12 /PRNewswire/ -- Celator Pharmaceuticals today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the company's CombiPlexÂ® technology platform (U.S.
ROCKAWAY, N.J., Dec.
A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation.
SAN DIEGO, Dec. 7 /PRNewswire/ -- Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.
PRINCETON, N.J., Dec.
PRINCETON, N.J., Oct.
Obesity is an important factor contributing to chemotherapy resistance and increasing relapse rates among children with leukemia, according to recent findings published online first in Cancer Research, a journal of the American Association for Cancer Research.
PRINCETON, N.J., Sept. 3 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston. Mr.
PRINCETON, N.J., June 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that new clinical and preclinical data demonstrating the extended therapeutic bioavailability and tumor cell selectivity of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in leukemia were presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany, June 4-7, 2009 (Abstracts 1398 and 383). "These findings underscore the potential pharmacological and pharmacokinetic...
PRINCETON, N.J., May 13 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 2009 BIO International Convention in Atlanta. Mr.
- totally perplexed and mixed up.